- News & Features
Welcome Molly, our new CreakyJoints Blog Manager. As a patient with multiple chronic diseases, Molly will lend her insight, strength, and empathy to the CreakyJoints community.
This past year has had it ups and downs. Take a moment to read some of the perspectives that have been shared on the CreakyJoints website.
The first head-to-head study comparing one tumor necrosis factor (TNF) inhibitor with another found similar outcomes for certolizumab pegol and adalimumab.
“There is a long history of bias in healthcare in the United States against LGBT people and there are also significant healthcare disparities in these populations.”
The phrase “clear as mud” came up several times in the introduction Dr. William Harvey delivered at the 2016 ACR Annual Meeting about the Medicare Access and CHIP Reauthorization Act of 2015.
Preliminary findings link proton pump inhibitors (PPIs), drugs commonly used to reduce stomach acid and treat heartburn, to increased risk for ischemic stroke.
Researchers found that Rituximab was successful in treating a variety of autoimmune and immune-mediated cutaneous disorders.
A study found that the addition of voclosporin to standard treatment of acute lupus nephritis increased the speed of remission and overall remission rates.
A new report has identified population subgroups with greater prevalence of inflammatory bowel disease.
A new study suggests that lupus low disease activity state is "a much more clinically attainable state than the stricter definitions of remission."
The findings suggest that there are distinct types of knee osteoarthritis that might require different treatments.